Keywords: Fuzzy expert system; Response surface; Expertise; Nephropathy control; Type 2 diabetes mellitus; ANN; Artificial neural networks; CIs; confidence intervals; CPG; clinical practice guidelines; ES; Expert system (s); ESRD; End-stage renal disease; FES; Fuzz
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: CCA; circulating cathodic antigen; CIs; confidence intervals; KK; Kato-Katz; MDA; mass drug administration; MoHP; Ministry of Health and Population; NSCP; National Schistosomiasis Control Programme; WHO; World Health Organization; Urine-CCA; Kato-Katz; S.
Keywords: Sleep duration; All-cause mortality; Dose-response relationship; Meta-analysis; BMI; body mass index; CIs; confidence intervals; HRs; hazard ratios; MOOSE; meta-analysis of observational studies in epidemiology; NOS; Newcastle-Ottawa Scale; RRs; relat
Keywords: BMI; body mass index; BBzP; butyl benzyl phthalate; CIs; confidence intervals; DBP; dibutyl phthalate; DEHP; bis(2-ethylhexyl) phthalate; DEP; diethyl phthalate; DiBP; di-iso-butyl phthalate; DiDP; di-iso-decyl phthalate; DiNP; di-iso-nonyl phthalate; DMP
Keywords: Solar cells; Thin film; CdTe; CIS; Analytical model;
Keywords: AAB; Avoidance of Antibiotic Treatment for Adults with Acute Bronchitis; AAP; Adults' Access to Preventive/Ambulatory Health Services; ABA; Adult Body Mass Index Assessment; AMM; Antidepressant Medication Management; AWC; Adolescent Well-Care Visits; BC
Keywords: 5ALA; 5-aminolevulinic acid; CIS; carcinoma in situ; CTU; CT urogram; HAL; hexaminolaevulinate; HNPCC; non-polyposis colorectal carcinoma; NBI; narrow-band imaging; PDD; photodynamic diagnosis; PPIX; protoporphyrin IX; PRISMA; Preferred Reporting Items fo
Keywords: CIS; cisplatin; DXZ; doxazosin; DXZ-NC; doxazosin-loaded nanocapsules; MCT; medium chain triglycerides; PE; plate efficiency; SF; survival factor; UNC; unloaded nanocapsules; Antitumor; Apoptosis; Cell death; Clonogenic; MCF7 cells; Nanocapsules;
Keywords: HME; homemade explosive; IED; improvised explosive device; MODD; Mixed Odor Delivery Device; AN; ammonium nitrate; CIS; cooled injection system; Vapor; Vapor delivery; Canine detection; Explosives; Homemade explosives;
Keywords: CDMS; clinically definite MS; CIS; clinically isolated syndrome; CNS; central nervous system; DIS; dissemination in space; DIT; dissemination in time; DMT; disease-modifying therapies; NAA/Cr ratio; N-acetylaspartate/creatine ratio; NSWML; non-specific wh
Keywords: HD; Hirschsprung disease; RSB; Rectal suction biopsy; CIS; Calretinin immunohistochemical staining; RA; Residual aganglionosis; TZB; Transition zone bowel; Hirschsprung disease; Residual aganglionosis; Transition zone bowel; Rectal suction biopsy; Calreti
Keywords: C51; E; Q4; Energy-growth nexus; Oil-exporting Eurasian countries; Middle East; CIS; Panel Cointegration; Panel Granger causality;
Keywords: urinary bladder neoplasms; cystoscopy; aminolevulinic acid; photochemotherapy; drug-related side effects and adverse reactions; AE; adverse event; BLC; blue light cystoscopy; CIS; carcinoma in situ; CTCAE; Common Terminology Criteria for Adverse Events; F
Keywords: CDW; Clinical Data Warehouse; HEGP; Hôpital Européen Georges Pompidou; CIS; Clinical Information System; Electronic health record; Clinical datawarehouse; Institutional ethics committee; Clinical research; Clinical epidemiology; Health services research
Keywords: Diabetes mellitus; Glucagon-like peptide-1 agonists; Microvascular events; Macrovascular events; Retinopathy; Nephropathy; Cardiovascular events; GLP-1; Glucagon-like peptide-1; DM; Type 2 diabetes mellitus; CV; Cardiovascular; MI; Myocardial Infarction;
Keywords: urinary bladder neoplasms; cystectomy; stents; nephrostomy; percutaneous; neoplasm recurrence; local; BC; bladder cancer; CIS; carcinoma in situ; CSS; cancer specific survival; CT; computerized tomography; IVP; excretory urography; RC; radical cystectomy;
Keywords: BCG vaccine; cancer vaccines; cell cycle checkpoints; immunotherapy; urologic neoplasms; AE; adverse event; APC; antigen presenting cell; BCG; bacillus Calmette-Guérin; CAR; chimeric antigen receptor; CIS; carcinoma in situ; CTA; cancer testis antigen; C
Keywords: APS; analytical performance specifications; BA; basophils; BAPS; analytical performance specification for bias; BV; biological variation; CBC; complete blood count; CIs; confidence intervals; CPD; cell population data; CVA; analytical variation; CVAPS; an
Keywords: Cornea; Conjunctiva; Lymphoma; Melanoma; Ocular surface squamous neoplasia (OSSN); Optical coherence tomography (OCT); Pterygium; Tumor; CIS; carcinoma in situ; HR-OCT; high resolution optical coherence tomography; LSCD; limbal stem cell deficiency; MMP;
Keywords: carcinoma; transitional cell; recurrence; prognosis; nomograms; CHAID; chi-square automatic interaction detection; CIS; carcinoma in situ; F1; F measure; LND; lymphadenectomy; LOOCV; leave-one-out cross-validation; LVI; lymphovascular invasion; RFS; relap
Keywords: Cancer Screening; Risk Stratification; Cost Effectiveness; Individualized Assessment; AIC; Akaike information criterion; AUC; area under the curve; BMI; body mass index; CI; confidence interval; CIS; carcinoma in situ; ESCC; esophageal squamous cell carci
Keywords: organ sparing treatments; penile neoplasms; treatment outcome; quality of life; CIS; carcinoma in situ; FS; frozen section; GL; glansectomy; GR; glans resurfacing; IIEF-15; International Index of Erectile Function; MMS; Mohs micrographic surgery; Nd:YAG;
Keywords: CDMS; Clinically Definite Multiple Sclerosis; CI; Confidence Interval; CIS; Clinically Isolated Syndrome; CNS; Central Nervous System; EBV; Epstein-Barr Virus; GRADE; Grading of Recommendations Assessment, Development, and Evaluation; HLA; Human Leukocyte
Keywords: CC; carbon-carbon double bond; COOH; carboxyl; Cy; cyanidin; Dp; delphinidin; E; trans; GC; p-coumaryl-glucose unit; Mv; malvidin; OH; hydroxyl; Pg; pelargonidin; pKH; hydration constant; Pn; peonidin; Pt; petunidin; SAR; structure-activity relationsh
Keywords: AIDE; Adsorption Induced Dislocation Emission; API; American Petroleum Institute; ASME; American Society of Mechanical Engineers; BS; British Standards; CP; Cathodic Protection; CIS; Close Interval Survey; CSE; Copper Sulfate Electrode; LME; Liquid Metal
Keywords: ALS; acid-labile subunit; CIS; cytokine-inducible SH2-containing protein; E2; estradiol; ER; endoplasmic reticulum; ERK; extracelular regulated kinase; ESPE; European Society for Pediatric Endocrinology; GH; growth hormone; GHBP; growth hormone binding pr
Keywords: Sleep; Breast cancer; Black women; Hormone receptor-positive breast cancer; Hormone receptor-negative breast cancer; BMI; body mass index; CIs; confidence intervals; MET; metabolic equivalent; MHT; menopausal hormone therapy; MVPA; moderate-to-vigorous ph
Keywords: Oral cancer; Oral premalignant lesions; Dysplasia; Treatment; Cancer progression; SCC; squamous cell carcinoma; CIS; carcinoma in situ; BC; British Columbia;
Keywords: AC; anticoagulation; APS; antiphospholipid antibody syndrome; CIs; confidence intervals; CVRN VTE; Cardiovascular Research Network Venous Thromboembolism; DVT; deep vein thrombosis; ICD-9; International Classification of Diseases 9th Revision; Ig; immunog
Keywords: PD; Parkinson's disease; ORs; odds ratios; CIs; confidence intervals; COX2; cyclooxygenase 2; IL-1β; interleukin-1β; O3; ozone; PM2.5; particulate matter with an aerodynamic diameter â¦Â 2.5 μm; PM10; particulate matter with an aerodynamic diameter â
Keywords: BBB; blood-brain barrier; CIS; clinically isolated syndrome; CNS; central nervous system; CSF; Cerebrospinal Fluid; EBV; Epstein-Barr virus; HERVs; Human endogenous retroviruses; HERV-W; W family of human endogenous retroviruses; MRI; magnetic resonan
Keywords: urinary bladder neoplasms; cystectomy; neoplasm recurrence; local; patient selection; morbidity; BCa; bladder cancer; BCG; bacillus Calmette-Guérin; CG; Clavien grade; CIS; carcinoma in situ; DSS; disease specific survival; LVI; lymphovascular invasion;
Keywords: M10; M19; Innovation; R&D; Healthcare Sector; CIS;
Keywords: AAO; age at onset; CIs; confidence intervals; GBA; glucocerebrosidase; LRRK2; leucine-rich repeat kinase 2; MAPT; microtubule-associated protein tau; NOS; Newcastle-Ottawa Scale; ORs; odds ratios; PD; Parkinson's disease; SNCA; a-Synuclein; meta-analy
Keywords: CHD; coronary heart disease; DALYs; disability-adjusted life years; RRs; relative risks; CIs; confidence intervals; Sleep duration; Coronary heart disease; Systematic review;
Keywords: Innovation; Cooperation; External relationships; Organizational innovation; CIS;
Keywords: Irisin; Insulin resistance; Meta-analysis; CIs; confidence intervals; FNDC5; fibronectin type-III domain containing protein 5; MOOSE; Meta-analysis of Observational Studies in Epidemiology; BMI; body mass index; STROBE; Strengthening the Reporting of Obse
Keywords: TF; Technology Forecasting; IRL; Innovation Readiness Level; EF Techs; Emerging Future Technologies; BMI; Brain Machine Interface; RNA; Ribo-Nucleic Acid; IoE; Internet of Everything; iPS; induced Pluripotent Stem Cell; IPC; International Patent Classific
Keywords: Auditory nerve; Cochlear implants; Model; Adaptation; Stochasticity; SFAP; Single Fiber Action Potential; CIS; Continuous Interleaved Sampling; CI; Cochlear Implant; RS; Relative Spread; eCAP; electrically evoked Compound Action Potential; ARP; Absolute R
Keywords: 2D; two-dimensional; 3D; three-dimensional; APC; adenomatous polyposis coli; BCC; basal cell carcinoma; BM; basement membrane; CEA; carcinoembryonic antigen; CIS; carcinoma in situ; CNS; central nervous system; ECM; extracellular matrix; IHC; immunohistoc
Keywords: TCM; traditional Chinese medicine; NHI; National Health Insurance; LHID; Longitudinal Health Insurance Database; ICD-9-CM; International Classification of Disease 9th Revision of the Clinical Modification; COPD; chronic obstructive pulmonary disease; CAD;
Keywords: AAN; American Academy of Neurology; ABN; Association of British Neurologists; AUD; Australian dollars; CIS; clinically isolated syndrome; CNS; central nervous system; DMT; disease-modifying therapy; EDSS; Kurtzke Expanded Disability Status Scale; EMA; Eur
Keywords: acquired demyelinating syndrome; children; multiple sclerosis; ADEM; CIS; transverse myelitis
Keywords: urinary bladder neoplasms; biopsy; neoplasm recurrence; local; cystoscopy; cytology; BCG; bacillus Calmette-Guérin; CIS; carcinoma in situ; CT; computerized tomography; PFS; progression-free survival; RFS; recurrence-free survival; TURBT; transurethral r
Keywords: urinary bladder neoplasms; ureteral neoplasms; cystectomy; frozen section; biopsy; CIS; carcinoma in situ; DSS; disease specific survival; IUFS; intraoperative ureteral frozen section; OS; overall survival; UTR; upper tract recurrence;
Keywords: AUC; the area under the summary receiver operating characteristic curve; CAD; coronary artery disease; CCTA; coronary computed tomography angiography; CIs; confidence intervals; DOR; diagnostic odds ratio; FP; false positive; FN; false negative; FFR; frac
Keywords: BYU; Brigham Young University; CI; cochlear implant; CIC; channel interaction compensation; CIS; continuous interleaved sampling; CSSS; channel-specific sampling sequences; ENT; ear nose throat; FS; fine structure; FSP; fine structure processing; MCL; mos
Keywords: AUC; area under the curve; CIS; carcinoma in situ; IQR; interquartile range; NBI; narrow band imaging; OB; optical biopsy; PD; photodynamic diagnostic; PDT; photodynamic therapy; PPIX; protoporphyrin IX; US; ultrasonography; Optical spectrometry; Optical
Keywords: PAHs; Polycyclic aromatic hydrocarbons; CVD; Cardiovascular disease; T2DM; Type 2 diabetes mellitus; PM; Particulate matter; MetS; Metabolic syndrome; OH-PAHs; Monohydroxy urinary metabolites of PAHs; HOMA2; Updated Homeostasis Model Assessment; NHANES; N
Keywords: AMCase; acidic mammalian chitinase; BRP-39; breast regression protein 39; CHI3L1; chitinase 3-like 1; CHI3L3; chitinase 3-like 3; CHIT-1; chitotriosidase; CIS; clinically isolated syndrome; CNS; central nervous system; EAE; experimental autoimmune encepha